AR019305A1 - Hiv y tratamiento viral. - Google Patents

Hiv y tratamiento viral.

Info

Publication number
AR019305A1
AR019305A1 ARP990102384A ARP990102384A AR019305A1 AR 019305 A1 AR019305 A1 AR 019305A1 AR P990102384 A ARP990102384 A AR P990102384A AR P990102384 A ARP990102384 A AR P990102384A AR 019305 A1 AR019305 A1 AR 019305A1
Authority
AR
Argentina
Prior art keywords
hiv
virus
hydrogen
less
delay
Prior art date
Application number
ARP990102384A
Other languages
English (en)
Spanish (es)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR019305A1 publication Critical patent/AR019305A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP990102384A 1998-05-19 1999-05-19 Hiv y tratamiento viral. AR019305A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8138498A 1998-05-19 1998-05-19

Publications (1)

Publication Number Publication Date
AR019305A1 true AR019305A1 (es) 2002-02-13

Family

ID=22163807

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102384A AR019305A1 (es) 1998-05-19 1999-05-19 Hiv y tratamiento viral.

Country Status (19)

Country Link
US (1) US6245789B1 (ko)
EP (1) EP1079831A1 (ko)
JP (1) JP2002515432A (ko)
KR (1) KR20010043709A (ko)
CN (1) CN1301158A (ko)
AR (1) AR019305A1 (ko)
AU (1) AU4004299A (ko)
BR (1) BR9911043A (ko)
CA (1) CA2329877A1 (ko)
CO (1) CO5050303A1 (ko)
HU (1) HUP0103319A2 (ko)
ID (1) ID27457A (ko)
IL (1) IL139002A0 (ko)
NO (1) NO20005839L (ko)
PE (1) PE20000550A1 (ko)
PL (1) PL344223A1 (ko)
SK (1) SK17442000A3 (ko)
TR (1) TR200003383T2 (ko)
WO (1) WO1999059585A1 (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6242461B1 (en) * 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) * 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
AU2002239395A1 (en) * 2000-11-01 2002-06-03 The Procter And Gamble Company Hiv treatment with benzimidazoles
DE60112609T2 (de) 2000-12-15 2006-01-19 Glaxo Group Ltd., Greenford Pyrazolopyridine
AU2002239348A1 (en) 2000-12-15 2002-06-24 Glaxo Group Limited Pyrazolopyridine derivatives
EP1366048B1 (en) 2001-03-08 2004-08-25 SmithKline Beecham Corporation Pyrazolopyridine derivatives
EP1372643A1 (en) 2001-03-30 2004-01-02 Smithkline Beecham Corporation Pyrazolopyridines, process for their preparation and use as therapeutic compounds
EP1377575B1 (en) 2001-04-10 2006-07-05 SmithKline Beecham Corporation Antiviral pyrazolopyridine compounds
JP2004527560A (ja) 2001-04-27 2004-09-09 スミスクライン ビーチャム コーポレーション ピラゾロ［１，５−α］ピリジン誘導体
CA2451008A1 (en) 2001-06-21 2003-01-03 Smithkline Beecham Corporation Imidazo[1,2-a!pyridine derivatives for the prophylaxis and treatment of herpes viral infections
ES2262893T3 (es) 2001-10-05 2006-12-01 Smithkline Beecham Corporation Derivados de imidazo-piridina para su uso en el tratamiento de infeccion virica por herpes.
ES2292839T3 (es) * 2001-12-11 2008-03-16 Smithkline Beecham Corporation Derivados de pirazolo-piridina como agentes contra el herpes.
JP2005521712A (ja) * 2002-03-26 2005-07-21 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ 弱塩基の可溶化
EP1546148A1 (en) 2002-10-03 2005-06-29 SmithKline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
AU2003900064A0 (en) * 2003-01-09 2003-01-23 Penam Investments Pty. Ltd. A method of treatment or prophylaxis of viral infection.
JP2005060362A (ja) * 2003-07-28 2005-03-10 Shionogi & Co Ltd セスキテルペン誘導体を含有する抗ＨＩＶ剤、抗ＢＶＤＶ剤、抗ＨＣＶ剤又は抗ＣｏＶ剤
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
MX2015013142A (es) * 2013-03-15 2016-05-18 Camas Inc Métodos y composiciones para reducir microorganismos en la orofaringe, nasofaringe y cavidades orales.
FR3057865A1 (fr) * 2016-10-21 2018-04-27 Laboratoire Michel Iderne Composition chimique
TW201936193A (zh) * 2017-12-05 2019-09-16 愛爾蘭商健生科學愛爾蘭無限公司 使用組合產品治療ｒｓｖ
KR102342313B1 (ko) * 2021-08-27 2021-12-24 (주)바이오메트릭스 테크놀로지 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010968A (en) 1959-11-25 1961-11-28 Du Pont Process for manufacture of certain alkyl esters of benzimidazole carbamic acids
NL134354C (ko) 1963-05-23
US3499761A (en) 1964-07-20 1970-03-10 Gaf Corp Silver halide emulsions containing alkyl esters of benzimidazole carbamic acid antifogging agents
US3541213A (en) 1966-05-06 1970-11-17 Du Pont Fungicidal and mite ovicidal substituted 2-aminobenzimidazoles
US3881014A (en) 1968-11-05 1975-04-29 Bayer Ag N-tritylimidazoles for treating fungal infections
BE759337A (fr) 1969-11-24 1971-05-24 Lilly Co Eli Benzimidazol (2,1-b)-quinazolin (6h) ones qui sont des immuno-depresseurs, et nouvelles benzimidazo (2,1-b) quinazolin-12-(6h) ones
US3956262A (en) 1970-12-09 1976-05-11 Beecham Group Limited Triazenoimidazoles
US3738995A (en) 1971-05-14 1973-06-12 Du Pont Solvent process for the preparation of 1 - carbamoyl-substituted 2 - benzimidazolecarbamates
FR2155888A1 (en) 1971-10-13 1973-05-25 Agot Aime Solid anthelmintic composn - for more economical treatment of ruminants
US4046906A (en) 1973-04-21 1977-09-06 Hoechst Aktiengesellschaft Salts of alkyl 2-benzimidazole-carbamate
HU193951B (en) 1985-03-11 1987-12-28 Richter Gedeon Vegyeszet Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them
US4731366A (en) 1986-08-05 1988-03-15 Harbor Branch Oceanographic Institution, Inc. Discorhabdin compositions and their methods of use
GB2210875B (en) 1987-10-09 1991-05-29 Farmos Oy Aromatase inhibiting 4(5)-imidazoles
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
US5114951A (en) 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance
US5149527A (en) 1990-09-18 1992-09-22 Oncotech, Inc. Immunopotentiating protocol for chemotherapy-responsive tumors
US5364875A (en) 1992-05-11 1994-11-15 The Du Pont Merck Pharmaceutical Company Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis
US5310748A (en) 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
US5290801A (en) 1992-05-29 1994-03-01 The Du Pont Merck Pharmaceutical Company Benzimidazoles for the treatment of atherosclerosis
EP0655066A1 (en) 1992-08-12 1995-05-31 PHARMACIA & UPJOHN COMPANY Protein kinase inhibitors and related compounds combined with taxol
PL310895A1 (en) 1993-03-31 1996-01-08 Merck & Co Inc Hiv protease inhibitors in aids treating pharmaceutic compositions
US5434163A (en) 1993-05-14 1995-07-18 The Medical College Of Pennsylvania Treatment of Cryptococcus neoformans infection
JP3213471B2 (ja) 1994-04-13 2001-10-02 ポーラ化成工業株式会社 薬効成分含有リポソーム製剤の製造方法
CZ323597A3 (cs) 1995-04-12 1998-03-18 The Procter & Gamble Company Farmaceutický prostředek obsahující N-chlorfenylkarbamáty a N-chlorfenylthiocarbamaty pro inhibici růstu virů a karcinom
US5656615A (en) 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
NZ305784A (en) 1995-04-12 2001-03-30 Procter & Gamble Benzimidazole containing medicaments for treating cancers, tumors and viral infections
US5665713A (en) 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
ZA962879B (en) * 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
US5629341A (en) 1995-04-12 1997-05-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
ZA962880B (en) 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US5665751A (en) 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
MX9707809A (es) 1995-06-07 1998-01-31 Procter & Gamble Una composicion farmaceutica que contiene bencimidazol para inhibir el crecimiento de canceres.
US6200992B1 (en) 1995-06-07 2001-03-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
CZ391197A3 (cs) 1995-06-07 1998-05-13 The Procter & Gamble Company Použití benzimidazolů pro přípravu léčiva pro léčení leukémie
JPH11511136A (ja) 1995-08-03 1999-09-28 ザ プロクター アンド ギャンブル カンパニー 癌の成長を阻害するためのグリセオフルビンの使用
PL324904A1 (en) 1995-08-04 1998-06-22 Procter & Gamble Application of fluconazole in carcinoma development inhibition
US5908855A (en) 1996-07-16 1999-06-01 The Procter & Gamble Company Compositions for treating viral infections
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
PE11499A1 (es) 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment

Also Published As

Publication number Publication date
IL139002A0 (en) 2001-11-25
PE20000550A1 (es) 2000-06-29
BR9911043A (pt) 2001-02-13
TR200003383T2 (tr) 2001-03-21
CO5050303A1 (es) 2001-06-27
AU4004299A (en) 1999-12-06
EP1079831A1 (en) 2001-03-07
NO20005839D0 (no) 2000-11-17
ID27457A (id) 2001-04-12
US6245789B1 (en) 2001-06-12
PL344223A1 (en) 2001-10-08
HUP0103319A2 (hu) 2002-05-29
KR20010043709A (ko) 2001-05-25
SK17442000A3 (sk) 2001-08-06
NO20005839L (no) 2001-01-16
WO1999059585A1 (en) 1999-11-25
JP2002515432A (ja) 2002-05-28
CA2329877A1 (en) 1999-11-25
CN1301158A (zh) 2001-06-27

Similar Documents

Publication Publication Date Title
AR019305A1 (es) Hiv y tratamiento viral.
CO5160294A1 (es) Composicion farmaceutica que inhibe o detiene el crecimiento de virus en animales particularmente mamiferos sarrollo de virus en animales y composiciones farmaceuticas que los contienen
BR0312271A (pt) compostos, composições e seus usos para o tratamento de infecções por flaviviridae
RS114104A (en) 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
BR0213522A (pt) Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids
UY27466A1 (es) Métodos y composiciones para el tratamiento de hepatitis c virus con 4'-modificaciones nucleosides
AR012964A1 (es) Compuetos derivados de bencimidazol, composiciones farmaceuticas que los contienen y su uso en la manufactura de medicamentos para tratar infeccionesvirales
HUP0001170A2 (hu) Hatóanyagként enzimidazol-2-karbamát-származékokat tartalmazó, vírusfertőzések és rák kezelésére alkalmas gyógyszerkészítmények
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
TW427887B (en) Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections
EA200600227A1 (ru) Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов
AR018706A1 (es) Uso de una composicion farmaceutica para tratamiento de infecciones virales
HUP9900901A2 (hu) N-(Klór-fenil)-karbamátokat és N-(klór-fenil)-tiokarbamátokat tartalmazó, rákellenes és vírusok szaporodását gátló gyógyszerkészítmény
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
BR0314695A (pt) Composto, processo para preparar um composto, processo para preparar um estereoisÈmero de um composto, composição para o tratamento de doenças virais, e, composição para o tratamento da hepatite b
CO5080752A1 (es) INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB
PE61699A1 (es) Composicion farmaceutica de lamivudina
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체
WO2002041891A3 (en) Hiv treatment with benzimidazoles
AR016386A1 (es) D- o l-lixofuranosil benzimidazoles composicion que los contiene, procedimiento para su preparacion y su uso para la manufactura de un medicamento
ATE192926T1 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
KR910021407A (ko) 바이러스에 의해 유발된 질환을 치료하기 위한 벤질포스폰산 유도체의 용도
AR018707A1 (es) Composicion farmaceutica para tratar infecciones virales
KR900002787A (ko) 인체 후천성 면역부전증후군 바이러스 감염 저해제